• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Platelets and COVID-19
Hamostaseologie. 2021 Oct;41(5):379-385. doi: 10.1055/a-1581-4355. Epub 2021 Oct 25.ABSTRACTIn 2019 first reports about a new human coronavirus emerged, which causes common cold symptoms as well as acute respiratory distress syndrome. The virus was identified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and severe thrombotic events including deep vein thrombosis, pulmonary embolism, and microthrombi emerged as additional symptoms. Heart failure, myocardial infarction, myocarditis, and stroke have also been observed. As main mediator of thrombus formation, platelets became one of the key aspects in SARS-C...
Source: Hamostaseologie - October 25, 2021 Category: Hematology Authors: Anne-Katrin Rohlfing Dominik Rath Tobias Geisler Meinrad Gawaz Source Type: research

Protein S: function, regulation, and clinical perspectives
Purpose of review Protein S (PS) is an essential natural anticoagulant. PS deficiency is a major contributor to acquired hypercoagulability. Acquired hypercoagulability causes myocardial infarction, stroke, and deep vein thrombosis in millions of individuals. Yet, despite its importance in hemostasis, PS is the least understood anticoagulant. Even after 40 years since PS was first described, we are still uncovering information about how PS functions. The purpose of this review is to highlight recent findings that advance our understanding of the functions of PS and explain hypercoagulability caused by severe PS defic...
Source: Current Opinion in Hematology - August 6, 2021 Category: Hematology Tags: HEMOSTASIS AND THROMBOSIS: Edited by Paul F. Bray Source Type: research

Complement dysregulation is associated with severe COVID-19 illness
Haematologica. 2021 Jul 22. doi: 10.3324/haematol.2021.279155. Online ahead of print.ABSTRACTSevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2) may manifest as thrombosis, stroke, renal failure, myocardial infarction, and thrombocytopenia, reminiscent of other complement-mediated diseases. Multiple clinical and preclinical studies have implicated complement in the pathogenesis of COVID-19 illness. We previously found that the SARS-CoV-2 spike protein activates the alternative pathway of complement (APC) in vitro through interfering with the function of complement factor H, a key negative regulator of APC. Here, w...
Source: Haematologica - July 22, 2021 Category: Hematology Authors: Jia Yu Gloria F Gerber Hang Chen Xuan Yuan Shruti Chaturvedi Evan M Braunstein Robert A Brodsky Source Type: research

Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine: COMMENT: COMMENT from Gruel et al.: RESPONSE from Kahn et al
J Thromb Haemost. 2021 Jul 17. doi: 10.1111/jth.15467. Online ahead of print.ABSTRACTWe acknowledge the commentary of Gruel et al. on our recent letter [1] and are pleased that the authors agree that IdeS may be a potential treatment option for the rare but potentially severe IgG-mediated platelet activation observed in complications to vaccination with ChAdOx1 nCoV-19. It is apparent that our respective but distinct expertise with regard to IdeS has led us to develop this hypothesis in parallel. As we clearly cited in our original letter these authors have previously contributed important evidence that IdeS may be benefic...
Source: Thrombosis and Haemostasis - July 17, 2021 Category: Hematology Authors: Fredrik Kahn Oongh Shannon Lars Bj örck Source Type: research

Pathogenic lipid-binding antiphospholipid antibodies are associated with severity of COVID-19
CONCLUSIONS: COVID-19 patients rapidly expand B1a cells secreting pathogenic lipid-binding aPL with broad thrombotic and inflammatory effects. The association with markers of inflammation and coagulation, clinical severity and mortality suggests a causal role of aPL in COVID-19 associated coagulopathy.PMID:34242469 | DOI:10.1111/jth.15455
Source: Thrombosis and Haemostasis - July 9, 2021 Category: Hematology Authors: Anne Hollerbach Nadine M üller-Calleja Denise Pedrosa Antje Canisius Martin F Sprinzl Tanja Falter Heidi Rossmann Marc Bodenstein Christian Werner Ingo Sagoschen Thomas M ünzel Oliver Schreiner Visvakanth Sivanathan Michael Reuter Johannes Niermann Pete Source Type: research

Warfarin anticoagulation in the Covid-19 pandemic: Telephone-based management at a regional hematology outpatient center in Joinville, Brazil
Oral anticoagulation (OA) is a well-established therapeutic approach for prevention of cardioembolic stroke and venous thromboembolism [1]. Adequate OA is a key element in reducing the high social burden, morbidity and mortality associated with cardiovascular diseases [2 –4]. In January 2020, the World Health Organization (WHO) declared COVID-19 a public health emergency of international concern. Since then, the strategy of social distancing has been adopted in most countries, with varying degrees of restriction and compliance.
Source: Thrombosis Research - July 9, 2021 Category: Hematology Authors: Kendra Lys Calixto Machado, Suzana Tanquella da Rosa, Soraya Dobner, Ivan Schneider Boettcher, Gilberto Comaru Pasqualotto, Adelina Elisabeth Lehmkuhl Lopes, Tain á de Araújo, Lysandra Patricia Luchtenberg Bolduan, Maria Daniela Holthausen Perico Colomb Tags: Letter to the Editors-in-Chief Source Type: research

Pages: 1  2  3  4  5  6